PUMA BIOTECHNOLOGY (PBYI) Stock: Buy, Sell, or Hold?
$8.08
+0.00 (+0.00%)
▲
5d:
-17.3%
30d:
-20.78%
90d:
-8.49%
QUANTITATIVE VERDICT
HOLD
MODERATE Confidence (73%)
Quality Score
60/100
Position
OVERSOLD
30-Day Fair Range
$9.61 – $10.77
Position: OVERSOLD
Forward P/E & Valuation
23.1x
STRETCHED
vs 18.1x historical avg
Wall Street Target
$6.00
-25.7% vs target
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$7.59 / $10.88
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 HOLD: PBYI trades at premium valuation expecting 8.4% growth. Hold existing positions but don't chase. Wait for better entry.
Get Alerted When PBYI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$2.43
Based on -16.2% avg growth
INTRINSIC VALUE TODAY
$1.51
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PBYI is currently trading at $8.08, which is considered oversold relative to its 30-day fair value range of $9.61 to $10.77. From a valuation perspective, the stock is trading at a premium (Forward PE: 23.1) compared to its historical average (18.1). At these levels, the market is pricing in 8.4% annual earnings growth.
Technical Outlook: Technically, PBYI is in a strong uptrend. Immediate support is located at $7.59, while resistance sits at $10.88.
Market Sentiment: The stock scores a mixed 53/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. However, the stock is trading significantly above the average Wall Street target of $6.00. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PBYI is in a strong uptrend. Immediate support is located at $7.59, while resistance sits at $10.88.
Market Sentiment: The stock scores a mixed 53/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. However, the stock is trading significantly above the average Wall Street target of $6.00. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$9.61 -
$10.77
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
73.3%
Trading Range & Key Levels
30-Day Trading Range
$9.61 -
$10.77
Current vs Trading Range
OVERSOLD
Support Level
$7.59
Resistance Level
$10.88
Current Trend
Strong Uptrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (53/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 25.7% above Wall St target ($6.00)
- BULLISH: Expecting earnings turnaround to 8.4% growth with 1.1% revenue growth
- NEUTRAL: Bottoming setup forming (53/100) — watch for confirmation
- CAUTION: 5-day price weakness (-17.3%) - monitor closely
Fundamental Context
Forward P/E (Next Year Est.)
23.09
Wall Street Target
$6.00
(-25.7%)
Revenue Growth (YoY)
1.1%
Earnings Growth (YoY)
-35.3%
Profit Margin
10.3%
Valuation Premium vs History
+8.4% premium
PE vs Historical
23.1 vs 18.1
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+8.4%
(market-implied from PE analysis)
1-Year Target
$8.76
(+8%)
2-Year Target
$9.49
(+18%)
3-Year Target
$10.29
(+27%)
3-Yr Target (if PE normalizes)
(PE: 23→18)
PE COMPRESSION
$8.07
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 23.1, Growth: -36.4%)
$5.89
(+-27%)
Base:
(SPY PE: 19.9, Growth: -36.4%)
$5.07
(-37%)
Bear:
(PE: 16.9, Growth: -36.4%)
$4.31
(-47%)
📈
Valuation based on Current Earnings
Trailing PE: 17.57 | Current EPS (TTM): $0.46
Bull Case
$6.76
(-16%)
Analyst growth -23.9%, PE expands to 19.3
Base Case
$6.15
(-24%)
Market implied -23.9%, PE stable at 17.6
Bear Case
$5.49
(-32%)
Severe decline -20.0%, PE contracts to 14.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share PBYI Analysis
Share this live PBYI analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (PBYI)
Bullish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 5, 2026
Daily AI digest
AI Retail Discussion Summary:
Adma Biologics reported Q3 earnings and revenues that surpassed estimates, leading to a bullish sentiment on StockTwits.
Key Retail Themes:
earnings beat
revenue beat
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 13, 2026 4:24 AM ET
Data refreshes hourly during market hours. Next update: 5:24 AM
Data refreshes hourly during market hours. Next update: 5:24 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PBYI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 52 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 52 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$132 | 50 HOLD |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
21 analysts |
$17 | 37 SELL |
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
21 analysts |
$650 | 32 SELL |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive PBYI Research Pages
